Is the generic less effective than the original?

No — bioequivalence is demonstrated in cross-over studies on volunteers, with a ±20% range for AUC and Cmax (in practice, actually ±5-10%). The active substance, dose and form are identical. Only the excipients and the appearance differ.

Why does the price differ so much?

The originator invested billions in clinical research (10-15 years, phases I-III). After the patent expires, generics avoid these costs — they only run bioequivalence studies (1-2 years) and can sell much more cheaply.

Can I insist on the original brand at the pharmacy?

Yes, but you pay the whole difference above the CANAMED reference price. If your prescription said “do not substitute”, the pharmacy supplies the brand automatically and the reimbursement applies to that price.

They gave me a different generic this month. Is that OK?

For most medicines, yes — approved generics are bioequivalent to one another. Exceptions: antiepileptics, warfarin anticoagulants, levothyroxine, immunosuppressants — talk to your doctor.

Why does the pharmacist suggest a particular generic?

Several reasons: they have it in stock, a direct contract with the manufacturer (Terapia, Zentiva in Romania), the lowest price, confirmed quality. All ANMDMR-authorised generics are safe — the choice is among the approved ones.

How do I check that the generic is authorised?

On anm.ro → Human-use medicines register, search by INN or brand name. You see the CIM code, the MA, the manufacturer, the CANAMED price. Everything listed is legal and authorised.

Generic vs originator: bioequivalence, reference price, how to de

When the pharmacist tells you “there's a generic that costs half” for your atorvastatin prescription, what does that mean? Is it the same medicine? What is bioequivalence? And when does it make sense to pay the difference for the original brand? Here are the facts and the regulations that matter in Romania.

What a generic medicine is

A generic medicine is a copy of an original (brand) medicine whose patent protection rights have expired — in the EU, protection lasts 20 years from the patent filing, plus 5 years of SPC (Supplementary Protection Certificate) for pharmaceutical molecules, plus 10 years of data exclusivity. Total: ~25 years of protection for the originator.

After expiry, other manufacturers can produce and market the same medicine, provided they demonstrate bioequivalence — meaning the same therapeutic effect in the body.

Bioequivalence — the fundamental test

According to Directive 2001/83/EC and the EMA Bioequivalence Guideline (CHMP/EWP/QWP/1401/98 Rev. 1), a generic must demonstrate that it:

contains the same active substance (INN — International Nonproprietary Name), in the same amount;
has the same pharmaceutical form (tablets, capsules, syrup) or a pharmacotechnically equivalent one;
has key pharmacokinetic parameters — AUC (area under the curve) and Cmax (maximum plasma concentration) — within the 80-125% range relative to the originator (i.e. ±20% in cross-over studies on healthy volunteers).

This range may seem wide, but in practice approved generics fall within 90-110%, very close to the original. Differences greater than 20% do not pass ANMDMR (Romania's National Agency for Medicines and Medical Devices)/EMA evaluation.

What differs between a generic and the original

Excipients — the inert substances (lactose, starch, colourants). They can differ between manufacturers. Important for patients with intolerances (lactose), allergies to colourants (tartrazine E102), etc.
External appearance — colour, markings, packaging. Does not affect efficacy.
Place of manufacture — many generics are made in India, Slovenia (Krka), Cyprus, Hungary. The GMP (Good Manufacturing Practice) standard is identical — verified by EMA/ANMDMR.
Price — a generic typically costs 30-70% less than the originator, after the patent expires.

The reference price — how it is calculated

In Romania, CNAS (the National Health Insurance House) calculates a reference price per INN + strength + pharmaceutical form, used for reimbursement. Under OUG 12/2014 (Romanian Emergency Ordinance 12/2014, on the marketing of medicines):

the price of the cheapest generic on the CANAMED list (the official Romanian list of maximum medicine prices) for that INN is taken;
the reimbursement percentage (50%, 90%, 100%) is applied to that price;
if the patient wants the more expensive brand (originator), they pay the whole difference.

A concrete example — atorvastatin 20 mg:

Terapia generic: 12 RON / 30 tablets;
original Lipitor (Pfizer): 45 RON / 30 tablets;
CANAMED reference price: 12 RON;
90% reimbursement on sub-list A (the Romanian reimbursement sub-list A): 10.80 RON;
payment with the Terapia generic: 12 - 10.80 = 1.20 RON;
payment with original Lipitor: 45 - 10.80 = 34.20 RON.

The difference is fixed — the reimbursement system does not “punish” you for choosing the original, but neither does it help you above the reference price.

How to decide between generic and original

Cases where the generic is perfectly equivalent

antihypertensives (enalapril, ramipril, perindopril, amlodipine);
statins (atorvastatin, rosuvastatin, simvastatin);
classic oral antidiabetics (metformin, gliclazide);
common antibiotics (amoxicillin, clarithromycin, ciprofloxacin);
antiallergics (loratadine, cetirizine, desloratadine).

Cases worth discussing with your doctor

Antiepileptics — switching abruptly generic→original or vice versa can destabilise treatment. Recommendation: stay on the same manufacturer once stabilised.
Anticoagulants (warfarin) — the INR can vary on switching. Discuss it with your cardiologist.
Thyroid hormones (levothyroxine) — TSH rebalancing when the manufacturer changes. Not contraindicated, but check TSH at 6 weeks.
Post-transplant immunosuppressants (ciclosporin, tacrolimus) — narrow therapeutic index. Do NOT switch without your doctor.
Inhalers — differences in the device, not the molecule. The patient must be re-trained when the manufacturer changes.

Romanian generic manufacturers — context

The Romanian pharmaceutical industry has produced generic and OTC medicines since the 1970s (the socialist era), and its capacities were heavily modernised in 2000-2020 through private capital investment. Top manufacturers active in 2026:

Terapia Cluj-Napoca — founded 1921, acquired by Sun Pharma (India) in 2006. Broad generic portfolio for cardiology, diabetes, antibiotics. EU export capacity.
Antibiotice Iași — founded 1955, listed on the BVB (Bucharest Stock Exchange). Specialised in generic antibiotics, local anaesthetics, low-volume oncology products.
Labormed Pharma Bucharest — OTC + Rx generics, dermocosmetics. Acquired by Alvogen (USA) in 2011.
Zentiva Romania — part of Zentiva (Czech Republic / a Sanofi spinoff), broad generic portfolio.
Biofarm Bucharest — founded 1921, listed on the BVB. Generics + OTC + food supplements. An important Romanian brand.
Sintofarm Bucharest — low-cost generics, OTC.

These products circulate mainly on the Romanian market — with prices among the lowest in CANAMED — but are also exported within the EU (Bulgaria, Slovakia, Poland). Their quality meets EMA/GMP standards and is checked periodically. For the patient, choosing a Romanian generic is often the most economical option, with no compromise on safety.

Data exclusivity and its impact on generics

Beyond the invention patent (20 years), original medicines benefit from other protections that delay generics:

Data exclusivity — 8 years after the originator's MA (Marketing Authorisation), during which other companies cannot use its clinical-trial data to approve their own generic.
Marketing exclusivity — a further 2 years on top of data exclusivity (so 10 years in total). During these 10 years anyone can apply for generic registration but cannot sell.
The 1+1 extension — one extra year (so 11 years) if the originator obtains a new therapeutic indication within the first 8 years — a reward for clinical innovation.
Supplementary Protection Certificate (SPC) — extends the patent by up to 5 years to compensate for the time lost between filing and authorisation.

These cumulative protections explain why generics usually appear 12-15 years after the originator's launch (not immediately after the patent expires). For medicines launched in 2010-2015, generics start appearing en masse in the 2025-2030 period. For those launched in the 2000s, several generics are already available.

Biosimilars — the special category for biotech medicines

For biological medicines (monoclonal antibodies, analogue insulins, growth factors), the post-patent copy is not called a “generic” but a biosimilar. The difference is that a biological molecule cannot be copied identically (it is a protein complex), only produced so as to have the same functional structure. The approval process is much stricter — it requires comparative clinical studies, not just bioequivalence.

Examples in Romania in 2026:

Insulin glargine — Lantus (Sanofi originator) vs Abasaglar (Lilly biosimilar) vs Semglee (Mylan biosimilar). Both biosimilars are EMA-authorised and used extensively under CNAS.
Adalimumab — Humira (originator) vs Hyrimoz, Imraldi, Amgevita (biosimilars). Used in rheumatology and gastroenterology.
Trastuzumab — Herceptin (originator) vs Ontruzant, Kanjinti (biosimilars). Used in oncology for HER2+ breast cancer.
Erythropoietin — Eprex (originator) vs Binocrit, Retacrit (biosimilars). Used in nephrology and oncology.

For biosimilars, the switching decision is made exclusively by the specialist physician — not by the pharmacist. Biosimilar prices are 20-40% lower than the originator, which makes expensive treatments affordable under CNAS.

The pharmacist's right of substitution

Under Legea 95/2006, art. 793 (Romania's Law 95/2006 on healthcare reform), the pharmacist has the right (and the obligation, unless the prescription expressly forbids it) to propose a generic substitution. If the doctor has written “do not substitute” on the prescription or used the brand name with an express note, the pharmacist is not allowed to switch.

You, the patient, have the right to refuse the substitution — in which case you pay the whole difference above the reference price. Or to accept it — and save money.

How to check that a generic is authorised

All generics authorised in Romania appear on anm.ro → Human-use medicines register (Nomenclator). Each product has a CIM code (medicine identification code) and an MA (Marketing Authorisation; APP in Romanian). Reputable manufacturers in Romania: Terapia Cluj, Zentiva, Labormed Romania, Krka Slovenia, Sandoz, Egis, Slovakofarma, Antibiotice Iași.

Frequently asked questions

Is the generic less effective than the original?: No — bioequivalence is demonstrated in cross-over studies on volunteers, with a ±20% range for AUC and Cmax (in practice, actually ±5-10%). The active substance, dose and form are identical. Only the excipients and the appearance differ.
Why does the price differ so much?: The originator invested billions in clinical research (10-15 years, phases I-III). After the patent expires, generics avoid these costs — they only run bioequivalence studies (1-2 years) and can sell much more cheaply.
Can I insist on the original brand at the pharmacy?: Yes, but you pay the whole difference above the CANAMED reference price. If your prescription said “do not substitute”, the pharmacy supplies the brand automatically and the reimbursement applies to that price.
They gave me a different generic this month. Is that OK?: For most medicines, yes — approved generics are bioequivalent to one another. Exceptions: antiepileptics, warfarin anticoagulants, levothyroxine, immunosuppressants — talk to your doctor.
Why does the pharmacist suggest a particular generic?: Several reasons: they have it in stock, a direct contract with the manufacturer (Terapia, Zentiva in Romania), the lowest price, confirmed quality. All ANMDMR-authorised generics are safe — the choice is among the approved ones.
How do I check that the generic is authorised?: On anm.ro → Human-use medicines register, search by INN or brand name. You see the CIM code, the MA, the manufacturer, the CANAMED price. Everything listed is legal and authorised.